Chapter 3 – Breast Cancer
暂无分享,去创建一个
Mohsen Beheshti | A. Buck | A. Rezaee | M. Raderer | M. Beheshti | W. Langsteger | Markus Raderer | Werner Langsteger | Alireza Rezaee | Andreas Buck
[1] P A Salvadori,et al. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. , 2000, Clinical breast cancer.
[2] P. Conte,et al. Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[3] Thomas J. Smith,et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Rutgers,et al. Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I-III Breast Cancer: Comparison With Standard PET/CT. , 2016, AJR. American journal of roentgenology.
[5] E. Gontier,et al. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer , 2015, The Journal of Nuclear Medicine.
[6] Yiyan Liu. Role of FDG PET-CT in evaluation of locoregional nodal disease for initial staging of breast cancer. , 2014, World journal of clinical oncology.
[7] D. Hendler,et al. Uncommon reason for high fluorodeoxyglucose positron emission tomography uptake. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Schnitt,et al. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy , 2010, Modern Pathology.
[9] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[10] R. A. Valdés Olmos,et al. Molecular Imaging in Breast Cancer: From Whole-Body PET/CT to Dedicated Breast PET , 2012, Journal of oncology.
[11] A. Alavi,et al. False-Negative and False-Positive Results in FDG-PET and PET/CT in Breast Cancer. , 2009, PET clinics.
[12] V. Dilsizian,et al. SNMMI/ASNC/SCCT Guideline for Cardiac SPECT/CT and PET/CT 1.0* , 2013, The Journal of Nuclear Medicine.
[13] B. Kang,et al. The value of primary tumor 18F-FDG uptake on preoperative PET/CT for predicting intratumoral lymphatic invasion and axillary nodal metastasis , 2016, Breast Cancer.
[14] Mithat Gonen,et al. 18F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis , 2010, Journal of Nuclear Medicine.
[15] Radiation safety with positron emission tomography and computed tomography. , 2010, Seminars in ultrasound, CT, and MR.
[16] Sanjiv S Gambhir,et al. FDG-PET and beyond: molecular breast cancer imaging. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Bhattacharya,et al. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma , 2012, Nuclear medicine communications.
[18] A. Glas,et al. Impact of mammographic screening on the detection of good and poor prognosis breast cancers , 2011, Breast Cancer Research and Treatment.
[19] W. Oyen,et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] B R Rosen,et al. Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients , 2015, British Journal of Cancer.
[21] M. Blaufox,et al. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases , 2005, Breast Cancer Research and Treatment.
[22] Alexandre Cochet,et al. Role of positron emission tomography for the monitoring of response to therapy in breast cancer. , 2015, The Oncologist.
[23] M. Gonen,et al. Retrospective Analysis of 18F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years , 2014, The Journal of Nuclear Medicine.
[24] J. Vercher-Conejero,et al. Positron Emission Tomography in Breast Cancer , 2015, Diagnostics.
[25] S. Kwon,et al. Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast , 2015, Nuclear Medicine and Molecular Imaging.
[26] S. Rodenhuis,et al. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy , 2012, Breast Cancer Research and Treatment.
[27] J. Brade,et al. 18 F-FDG PET/CT for initial staging in breast cancer patients – Is there a relevant impact on treatment planning compared to conventional staging modalities? , 2015, European Radiology.
[28] W Bolch,et al. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances , 2015, Annals of the ICRP.
[29] D. Mankoff,et al. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Groheux,et al. 18F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging , 2013, The Journal of Nuclear Medicine.
[31] M. Piccart,et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] P. Goss,et al. Estrogen and the risk of breast cancer. , 2001, The New England journal of medicine.
[33] S. Mattsson,et al. Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[34] K. Kang,et al. Correlation between 18F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer , 2015, European Radiology.
[35] S Leide-Svegborn,et al. Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG. , 2010, Radiation protection dosimetry.
[36] I. Fogelman,et al. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. , 2006, Seminars in nuclear medicine.
[37] David A Mankoff,et al. FDG PET, PET/CT, and breast cancer imaging. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.